Drug Profile

Research programme: small molecule therapeutics - BridGene Biosciences/Lakefront Biotherapeutics

Latest Information Update: 10 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BridGene Biosciences; Galapagos NV
Developer BridGene Biosciences
Class Antineoplastics; Small molecules
Mechanism of Action Protein-protein interaction inhibitors; Rho GTP-binding protein inhibitors; Transcription factor inhibitors; WDR5 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 May 2026 Galapagos NV is now called Lakefront Biotherapeutics
28 Oct 2025 No recent reports of development identified for preclinical development in Cancer in USA
01 Aug 2024 BridGene Biosciences expands strategic collaboration with Galapagos to develop selective oral SMARCA2 PROTAC

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com